Maplight Report Ph 1 Result for Schizophrenia & Alzheimer’s Disease
02 Dec 2024 //
PR NEWSWIRE
Maplight Announces Completion Of Ph1 Trial For Novel M1/M4 Muscarinic Agonist
03 Jan 2024 //
PR NEWSWIRE
MapLight Therapeutics Closes $225 Million Series C Funding Round
30 Oct 2023 //
PR NEWSWIRE
Exclusive: Trailing Karuna, MapLight Therapeutics aims to improve schizophrenia
30 Oct 2023 //
ENDPTS